Comparative review of dopamine receptor agonists in Parkinson's disease

Ryan J. Uitti, J. Eric Ahlskog

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Limitations of long term levodopa therapy for Parkinson's disease represent a major problem in the management of many patients. Dopamine receptor agonists provide antiparkinsonian effects and their use is most clearly defined in the context of complications from levodopa therapy. As such, dopamine receptor agonists are useful adjunctive agents to levodopa. Because typical adverse effects of dopamine receptor agonists may differ from those of levodopa, combination therapy is often effective and well tolerated. A variety of dopamine receptor agonists, both ergot and non-ergot derivatives, are useful in the treatment of Parkinson's disease. Five dopamine receptor agonists are currently available for use throughout much of the world, and many more are in developmental phases. Varying pharmacodynamic and pharmacokinetic profiles allow selection of appropriate dopamine receptor agonists for specific clinical scenarios. Recently reported comparative studies also suggest certain prescribing recommendations.

Original languageEnglish (US)
Pages (from-to)369-388
Number of pages20
JournalCNS Drugs
Volume5
Issue number5
StatePublished - 1996

Fingerprint

Dopamine Agonists
Parkinson Disease
Levodopa
Antiparkinson Agents
Therapeutics
Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

Uitti, R. J., & Ahlskog, J. E. (1996). Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs, 5(5), 369-388.

Comparative review of dopamine receptor agonists in Parkinson's disease. / Uitti, Ryan J.; Ahlskog, J. Eric.

In: CNS Drugs, Vol. 5, No. 5, 1996, p. 369-388.

Research output: Contribution to journalArticle

Uitti, RJ & Ahlskog, JE 1996, 'Comparative review of dopamine receptor agonists in Parkinson's disease', CNS Drugs, vol. 5, no. 5, pp. 369-388.
Uitti, Ryan J. ; Ahlskog, J. Eric. / Comparative review of dopamine receptor agonists in Parkinson's disease. In: CNS Drugs. 1996 ; Vol. 5, No. 5. pp. 369-388.
@article{b621804753be4174a6fab8c918590b75,
title = "Comparative review of dopamine receptor agonists in Parkinson's disease",
abstract = "Limitations of long term levodopa therapy for Parkinson's disease represent a major problem in the management of many patients. Dopamine receptor agonists provide antiparkinsonian effects and their use is most clearly defined in the context of complications from levodopa therapy. As such, dopamine receptor agonists are useful adjunctive agents to levodopa. Because typical adverse effects of dopamine receptor agonists may differ from those of levodopa, combination therapy is often effective and well tolerated. A variety of dopamine receptor agonists, both ergot and non-ergot derivatives, are useful in the treatment of Parkinson's disease. Five dopamine receptor agonists are currently available for use throughout much of the world, and many more are in developmental phases. Varying pharmacodynamic and pharmacokinetic profiles allow selection of appropriate dopamine receptor agonists for specific clinical scenarios. Recently reported comparative studies also suggest certain prescribing recommendations.",
author = "Uitti, {Ryan J.} and Ahlskog, {J. Eric}",
year = "1996",
language = "English (US)",
volume = "5",
pages = "369--388",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Comparative review of dopamine receptor agonists in Parkinson's disease

AU - Uitti, Ryan J.

AU - Ahlskog, J. Eric

PY - 1996

Y1 - 1996

N2 - Limitations of long term levodopa therapy for Parkinson's disease represent a major problem in the management of many patients. Dopamine receptor agonists provide antiparkinsonian effects and their use is most clearly defined in the context of complications from levodopa therapy. As such, dopamine receptor agonists are useful adjunctive agents to levodopa. Because typical adverse effects of dopamine receptor agonists may differ from those of levodopa, combination therapy is often effective and well tolerated. A variety of dopamine receptor agonists, both ergot and non-ergot derivatives, are useful in the treatment of Parkinson's disease. Five dopamine receptor agonists are currently available for use throughout much of the world, and many more are in developmental phases. Varying pharmacodynamic and pharmacokinetic profiles allow selection of appropriate dopamine receptor agonists for specific clinical scenarios. Recently reported comparative studies also suggest certain prescribing recommendations.

AB - Limitations of long term levodopa therapy for Parkinson's disease represent a major problem in the management of many patients. Dopamine receptor agonists provide antiparkinsonian effects and their use is most clearly defined in the context of complications from levodopa therapy. As such, dopamine receptor agonists are useful adjunctive agents to levodopa. Because typical adverse effects of dopamine receptor agonists may differ from those of levodopa, combination therapy is often effective and well tolerated. A variety of dopamine receptor agonists, both ergot and non-ergot derivatives, are useful in the treatment of Parkinson's disease. Five dopamine receptor agonists are currently available for use throughout much of the world, and many more are in developmental phases. Varying pharmacodynamic and pharmacokinetic profiles allow selection of appropriate dopamine receptor agonists for specific clinical scenarios. Recently reported comparative studies also suggest certain prescribing recommendations.

UR - http://www.scopus.com/inward/record.url?scp=0029895570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029895570&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029895570

VL - 5

SP - 369

EP - 388

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 5

ER -